MarsBars
Dutch biotech NewAmsterdam Pharma (NASDAQ:NAMS) announced Wednesday that its oral anti-cholesterol therapy containing experimental drugs obicetrapib and ezetimibe reached all co-primary endpoints in a pivotal Phase 3 trial.
The company said it expects the data to support global regulatory submissions
